

QUEBEC: A LEADING HUB FOR BIOTECHNOLOGY SERVICES

The North American hub where innovation meets efficiency

BIOQUÉBEC
Life Sciences and Health Technologies



Why Choose Quebec

○ A UNIQUE SERVICE HUB

From research to commercialization, Quebec offers a complete value chain that accelerates the development of your biotechnologies.

○ RECOGNIZED SCIENTIFIC EXPERTISE

A highly skilled, bilingual workforce with extensive experience in international clinical research.

○ LEADERSHIP IN APPLIED ARTIFICIAL INTELLIGENCE

AI-driven technologies integrated throughout the development process to accelerate innovation and deliver more accurate results.

○ A DIVERSE AND REPRESENTATIVE POPULATION

A unique asset for clinical research and the validation of innovative solutions.

○ COMPREHENSIVE REGULATORY EXPERTISE

Recognized expertise in Canadian, U.S., European, and international regulatory frameworks, ensuring full compliance with global quality standards.

○ A CULTURE OF COLLABORATION

An interconnected ecosystem where each partner is connected to the right stakeholders to maximize impact.

In Quebec, biotechnology service organizations provide a continuum of expertise that spans the entire development cycle, offering an integrated, client-focused approach.

Stages of project development

RESEARCH

BASIC RESEARCH AND DISCOVERY

A world-class scientific ecosystem that transforms fundamental research into clinical innovation.


- **Internationally recognized academic institutions** renowned for biotechnology advancements.
- **State-of-the-art infrastructure** fostering multidisciplinary research and collaboration between academia and industry.
- **Strong support** for research through project funding programs and competitive R&D tax incentives.

ADVANCED DEVELOPMENT

PHASE I-III CLINICAL TRIALS

An agile, reliable, and internationally recognized clinical environment known for the quality, speed, and rigor of its trials.

- **Short regulatory timelines** enabling trial initiation in as little as 30 days after submission.
- **Efficient regulatory framework** with close collaboration between Health Canada and responsive ethics committees.
- **A structured clinical ecosystem** characterized by its network of public and private clinical institutions.
- **Support from specialized organizations** that enhance coordination, quality, and efficiency across provincial clinical trial activities.
- **Modern technological infrastructure** fully compliant with GCP standards.



EARLY INNOVATION

PRECLINICAL PHASE

An integrated sector that enables the rapid translation of scientific discoveries into clinical applications.

- **Specialized preclinical expertise** covering the entire development continuum.
- **A dense network of contract laboratories, research centers, and specialized institutes** offering advanced capabilities in biology, pharmacology, toxicology, and analytical chemistry.
- **Regulatory and financial support** that facilitates rapid progression to clinical trials.
- **GMP-compliant manufacturing capabilities** tailored to preclinical and clinical development needs.

COMMERCIALIZATION

FROM NEW DRUG APPLICATIONS TO POST-MARKET STUDIES

Capabilities that combine manufacturing, market access, and post-commercialization monitoring to accelerate entry into the North American market.

- **Connected clinical infrastructures** integrating biospecimen collection, electronic health data, and longitudinal patient follow-up.
- **Privileged access** to the North American market.
- **Extensive expertise in post-marketing studies and strong Real-World Evidence (RWE)** capabilities.
- **High-quality patient support programs** that promote treatment adherence, real-world data collection, and an enhanced patient experience.
- **Close collaboration** among biotech companies, CROs, CDMOs, and public institutions for post-approval studies and patient registries.